Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Cardiology/Vascular Diseases | Family Medicine
Search Medical Condition
Peripheral Arterial Disease (PAD) Clinical Trials
A listing of Peripheral Arterial Disease (PAD) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (169) clinical trials
Safe-Dcb Bard Research Study Summary
A Prospective, Multicenter, Single Arm, Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter in Arteries of the Superficial Femoral Artery (SFA) and Popliteal Artery (PA) (SAFE_DCB U.S. Registry) Purpose: The purpose of this patient registry is to assess the clinical use of the Lutonix® ...
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS)
The primary purpose of this study is to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death in patients with coronary or peripheral artery disease.
PAD? Type II Diabetes? Diabetic Foot Ulcers?
Endeavor Clinical Trials is conducting a research study evaluating the safety and efficacy of an intramuscular injection in people with Peripheral Artery Disease & Diabetic Foot Ulcers
Do you have Peripheral Artery Disease (PAD)?
If you are 50 years of age or older and suffer from pain in your lower legs, you may be eligible to participate in a clinical research study. This study will evaluate the safety and effectiveness of an investigational medication in reducing heart disease in individuals diagnosed with PAD. There ...
A Washington University research study seeks participants ages 40 and older.
The purpose of this research study is to apply investigational MRI techniques to check blood flow and oxygen in the lower legs and feet of people with and without diabetes, and with and without a foot wound. There are 3 to 4 visits that last 1 to 2 hours. Participation ...
Overweight/Obesity, in patients with Heart Disease
The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Which treatment the participants get is decided by chance. ...
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
The study will evaluate the safety and effectiveness of the Ranger™ drug-coated balloon to open and prevent the re-narrowing of your blood vessel. Paclitaxel is a commonly used drug in other commercially approved devices. The addition of the Paclitaxel drug coating on the balloon could improve the performance of a ...
Simplified and Easy Detection of Arterial Disease in Nursing Homes
Patients referred for an arterial vascular investigations of the lower limbs will be included. After signing the consent, all included patients will be assessed by the examination series, among which ABI measurement and an arterial Doppler ultrasound of the lower limbs +/- transcutaneous oxygen pressure recording in case of suspected ...
Effects of Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty (PTA) in Patients With LE-PAD
The objective of the present study was to evaluate the prognostic impact of prolonged dual antiplatelet therapy (DAPT) with acetylsalicylic acid plus clopidogrel on the incidence of major adverse cardiovascular events and major adverse limb events after percutaneous lower extremity revascularization in patients with lower extremity peripheral arterial disease (LE-PAD).
A Genomic Approach for Clopidogrel in Caribbean Hispanics
Despite the substantial work in cardiovascular pharmacogenomics published over the past decade, a fundamental gap remains in understanding whether the genomic diversity of Caribbean Hispanics accounts for high inter-individual variability of clinical outcomes to preventive dual antiplatelet therapy (DAPT) with Clopidogrel. Caribbean Hispanics are disproportionately affected by cardio-metabolic disorders, but ...